Regorafenib (REG) combined with irinotecan (IRI) versus IRI alone as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas (mGA): A randomized phase II trial (PRODIGE 58 – UCGI 35 – REGIRI)

ANNÉE

2023

AUTEURS

Samalin E,

CONGRÈS/REVUE

JFHOD